Literature DB >> 4303132

Dysfibrinogenemia in a patient with primary hepatoma. First observation of an acquired abnormality of fibrin monomer aggregation.

A von Felten, P W Straub, P G Frick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4303132     DOI: 10.1056/NEJM196902202800802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Dysfibrinogenemia associated with liver disease.

Authors:  J E Palascak; J Martinez
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 2.  Hepatoma--nature's model tumor. A review.

Authors:  F F Becker
Journal:  Am J Pathol       Date:  1974-01       Impact factor: 4.307

3.  Association of abnormal fibrin polymerisation with severe liver disease.

Authors:  G Green; L Poller; J M Thomson; I W Dymock
Journal:  Gut       Date:  1977-11       Impact factor: 23.059

4.  Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism.

Authors:  J Martinez; R R Holburn; S S Shapiro; A J Erslev
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

5.  Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.

Authors:  J Martinez; J E Palascak; D Kwasniak
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

6.  Abnormalities of serum cholinesterase isozyme in liver cirrhosis and hepatoma (Part II).

Authors:  S Matsuzaki; K Iwamura; M Itakura; T Katsunuma
Journal:  Gastroenterol Jpn       Date:  1980

7.  Acquired dysfibrinogenaemia in liver disease.

Authors:  J L Francis; D J Armstrong
Journal:  J Clin Pathol       Date:  1982-06       Impact factor: 3.411

8.  An immunological study of prothrombin in liver cirrhosis.

Authors:  A Girolami; G Patrassi; G Cappellato; V Quaino
Journal:  Blut       Date:  1980-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.